Rep. Marjorie Taylor Greene Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

Key Points

• Rep. Marjorie Taylor Greene bought shares in Novo Nordisk A/S, investing between $1,001 and $15,000 on August 28th, as disclosed in a filing on August 29th.
• Novo Nordisk A/S stock is currently valued at $56.51, with a market capitalization of $252.29 billion, and has seen its shares fluctuate between a 52-week low of $45.05 and a high of $139.74.
• Recent analyst ratings have downgraded Novo Nordisk A/S from "buy" to "hold," reflecting a more cautious outlook among Wall Street analysts.

Representative Marjorie Taylor Greene (R-Georgia) recently bought shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on August 29th, the Representative disclosed that they had bought between $1,001 and $15,000 in Novo Nordisk A/S stock on August 28th.

Representative Marjorie Taylor Greene also recently made the following trade(s):

• Purchased $1,001 - $15,000 in shares of UnitedHealth Group NYSE: UNH on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of Southern NYSE: SO on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of PepsiCo NASDAQ: PEP on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of Morgan Stanley NYSE: MS on 8/28/2025.
• Purchased $15,001 - $50,000 in shares of Exelon NASDAQ: EXC on 8/28/2025.
• Purchased $15,001 - $50,000 in shares of Ryman Hospitality Properties NYSE: RHP on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of MercadoLibre NASDAQ: MELI on 8/28/2025.
• Purchased $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 8/28/2025.

Novo Nordisk A/S Stock Up 0.7%

NYSE NVO opened at $56.51 on Tuesday. The stock has a fifty day moving average of $60.46 and a 200-day moving average of $68.12. The stock has a market capitalization of $252.29 billion, a P/E ratio of 15.52, a price-to-earnings-growth ratio of 1.96 and a beta of 0.66. Novo Nordisk A/S has a 52 week low of $45.05 and a 52 week high of $139.74. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.56 and a current ratio of 0.78.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating the consensus estimate of $0.93 by $0.04. The company had revenue of $11.69 billion during the quarter, compared to analysts' expectations of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th were paid a $0.4119 dividend. This represents a dividend yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S's dividend payout ratio (DPR) is 22.53%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on NVO shares. Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Saturday, August 2nd. Hsbc Global Res cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 31st. UBS Group cut Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research note on Tuesday, August 5th. BNP Paribas Exane raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price for the company in a research note on Wednesday, August 13th. Finally, BNP Paribas raised Novo Nordisk A/S from an "underperform" rating to a "neutral" rating in a research note on Wednesday, August 13th. Three investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $81.00.

Institutional Trading of Novo Nordisk A/S

A number of institutional investors have recently modified their holdings of NVO. Revolve Wealth Partners LLC lifted its holdings in shares of Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after purchasing an additional 200 shares in the last quarter. AQR Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 0.7% in the fourth quarter. AQR Capital Management LLC now owns 51,341 shares of the company's stock valued at $4,416,000 after purchasing an additional 353 shares in the last quarter. Rehmann Capital Advisory Group lifted its holdings in shares of Novo Nordisk A/S by 3.0% in the fourth quarter. Rehmann Capital Advisory Group now owns 14,260 shares of the company's stock valued at $1,227,000 after purchasing an additional 415 shares in the last quarter. Cypress Advisory Group LLC bought a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at about $284,000. Finally, Alaethes Wealth LLC lifted its holdings in shares of Novo Nordisk A/S by 1.0% in the fourth quarter. Alaethes Wealth LLC now owns 24,922 shares of the company's stock valued at $2,144,000 after purchasing an additional 256 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

About Representative Greene

Marjorie Taylor Greene (Republican Party) is a member of the U.S. House, representing Georgia's 14th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027. Greene (Republican Party) is running for re-election to the U.S. House to represent Georgia's 14th Congressional District. She declared candidacy for the 2026 election.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.